Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Bans Parallel Export Of 24 Drugs As Brexit Nears

The move should help protect industry’s no-deal stockpiles

Executive Summary

The UK government has drawn up a list of 24 medicines that must not be parallel exported to EU countries. The move is widely seen as a way of protecting stockpiles of drugs that have been built up to compensate for supply chain problems in the event of a no-deal Brexit.

You may also be interested in...



EU Parallel Trade: The ‘Most Effective Savings Tool Available’

The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.

UK Adds MMR Vaccine To Export Ban List

There are now 31 medicines on the UK’s list of products that cannot be parallel exported to other European Economic Area countries as part of government efforts to tackle drug shortages. The parallel trade industry has attacked the initiative for lack of transparency.

First UK Serious Shortage Protocol Issued For Fluoxetine

The first Serious Shortage Protocol has been issued by the DHSC to tackle supply disruptions for fluoxetine capsules. The protocol came into effect on 3 October 2019 and will expire at the end of the month.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS140948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel